% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • mahesh1014 mahesh1014 Apr 30, 2013 6:16 PM Flag

    AACR 2013 Conference on its way ...look at the slides Wooohooo

    CDX -1127 Now this is what Weightbayou and others are talking about ....If FDA does not fast track this , they are placing lives at risk...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Celldex may have a third potential (peak sales) blockbuster coming of age. The phase I study that started 18 months ago actually has a phase II component. I suspect this is one we will be hearing a lot about this year. Another shot on goal and Celldex's precision-targetted molecules with companion diagnostic approach is winning time and time again. That means there are years and years of growth ahead as new targets, molecules and diagnostics are brought forward. The future look very bright for Celldex stakeholders!

      Sentiment: Strong Buy

    • Yes. 1127 could be huge.
      Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
      Intervention: Drug: CDX-1127

3.26-0.10(-2.98%)Oct 25 4:00 PMEDT